

#### US011129703B2

## (12) United States Patent

Baker et al.

## (10) Patent No.: US 11,129,703 B2

\*Sep. 28, 2021 (45) Date of Patent:

### INTRALUMINAL DEVICE AND METHOD OF **FIXATION**

Applicant: BFKW, LLC, Grand Rapids, MI (US)

Inventors: Randal S. Baker, Grand Rapids, MI

(US); Frederick J. Walburn, Grand Rapids, MI (US); James A. Foote, Ada,

MI (US)

Assignee: **BFKW, LLC**, Ada, MI (US)

Subject to any disclaimer, the term of this Notice:

patent is extended or adjusted under 35

U.S.C. 154(b) by 387 days.

This patent is subject to a terminal dis-

claimer.

Appl. No.: 16/222,486

Dec. 17, 2018 (22)Filed:

#### (65)**Prior Publication Data**

US 2019/0125515 A1 May 2, 2019

#### Related U.S. Application Data

Continuation of application No. 15/163,030, filed on (63)May 24, 2016, now Pat. No. 10,182,901, which is a (Continued)

(51)Int. Cl.

(52)

A61F 2/04 (2013.01)A61F 5/00 (2006.01)(2013.01)

A61F 2/90

U.S. Cl. (2013.01); **A61F** 5/0079 (2013.01);

(Continued)

Field of Classification Search (58)

> CPC .. A61F 2/04; A61F 2/90; A61F 5/0076; A61F 5/0079; A61F 2002/044;

> > (Continued)

#### **References Cited** (56)

#### U.S. PATENT DOCUMENTS

9/1983 Wilkinson et al. 4,403,604 A 4,607,618 A 8/1986 Angelchik (Continued)

#### FOREIGN PATENT DOCUMENTS

0760696 B1 8/2001 1808888 A2 7/2007 (Continued)

### OTHER PUBLICATIONS

International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Jul. 30, 2012.


(Continued)

Primary Examiner — Philip R Wiest (74) Attorney, Agent, or Firm — Gardner Linn

#### (57)ABSTRACT

An intraluminal device and method of fixation of an intraluminal device at a recipient having an esophagus, a stomach with a cardiac portion and a GE junction between the esophagus and the cardiac portion of the stomach includes deploying the intraluminal device to the recipient. The intraluminal device has a wall defining a cardiac member that is configured to the size and shape of the cardiac portion of the stomach and deployed to the cardiac portion of the stomach and an esophageal member that is configured to the size and shape of a portion of the esophagus and deployed to the esophagus. The intraluminal device having a connector connected with the esophageal portion and cardiac portion and deployed to the GE junction. The wall is fixed to the recipient to resist distal migration of the wall. The fixing includes the wall having a wall characteristic that is configured to facilitate tissue ingrowth. The wall is temporarily fixed to the recipient to resist distal migration of the wall while tissue ingrowth occurs at the wall characteristic.

#### 27 Claims, 17 Drawing Sheets



#### Related U.S. Application Data

continuation of application No. 14/118,731, filed as application No. PCT/US2012/038480 on May 18, 2012, now Pat. No. 9,375,338.

- (60) Provisional application No. 61/488,194, filed on May 20, 2011, provisional application No. 61/607,338, filed on Mar. 6, 2012.
- (52) **U.S. Cl.**

CPC ... A61F 2002/044 (2013.01); A61F 2002/045 (2013.01); A61F 2220/0075 (2013.01); A61F 2250/0067 (2013.01)

(58) Field of Classification Search

CPC ...... A61F 2002/045; A61F 2220/0075; A61F 2250/0067

See application file for complete search history.

#### (56) References Cited

#### U.S. PATENT DOCUMENTS

8/1993 Bangs 5,234,454 A 4/1994 Berry 5,306,300 A 5,366,504 A 11/1994 Andersen et al. 4/1996 Gresl et al. 5,507,755 A 5,662,713 A 9/1997 Andersen et al. 5,741,279 A 4/1998 Gordon et al. 5,820,584 A 10/1998 Crabb 11/2000 Andersen et al. 6,146,416 A 7/2001 Kilcoyne et al. 6,264,700 B1 8/2001 6,280,415 B1 Johnson 11/2001 Kortenbach 6,312,437 B1 6,355,070 B1 3/2002 Andersen et al. 6,398,802 B1 6/2002 Yee 6,432,040 B1 8/2002 Meah 9/2002 Adams 6,447,533 B1 4/2003 Taylor 6,544,291 B2 5/2003 Deem et al. 6,558,400 B2 6/2003 Gabbay 6,572,627 B2 12/2003 Gannoe et al. 6,656,194 B1 6,675,809 B2 1/2004 Stack et al. 6,736,828 B1 5/2004 Adams et al. 6,740,121 B2 5/2004 Geitz 6,746,460 B2 6/2004 Gannoe et al. 6/2004 Geitz 6,755,869 B2 6,773,440 B2 8/2004 Gannoe et al. 6,800,081 B2 10/2004 Parodi 6,802,868 B2 10/2004 Silverman et al. 6,845,776 B2 1/2005 Stack et al. 6,916,332 B2 7/2005 Adams 11/2005 Berg et al. 6,960,233 B1 6,981,978 B2 1/2006 Gannoe 2/2006 Burnett 6,994,095 B2 2/2006 Gannoe et al. 6,994,715 B2 7,025,791 B2 4/2006 Levine et al. 7,033,373 B2 4/2006 de la Torre et al. 7,033,384 B2 4/2006 Gannoe et al. 5/2006 Kagan et al. 7,037,344 B2 7,044,979 B2 5/2006 Silverman et al. 6/2006 Hashiba et al. 7,066,945 B2 7,083,629 B2 8/2006 Weller et al. 7,083,630 B2 8/2006 DeVries et al. 8/2006 Berg et al. 7,087,088 B2 7,097,650 B2 8/2006 Weller et al. 7,097,665 B2 8/2006 Stack et al. 7,111,627 B2 9/2006 Stack et al. 12/2006 Stack et al. 7,146,984 B2 7,152,607 B2 12/2006 Stack et al. 7,211,114 B2 5/2007 Bessler et al. 5/2007 Kagan et al. 7,220,284 B2 6/2007 Ramer 7,232,461 B2 3/2008 Levine et al. 7,347,875 B2 7,431,725 B2 10/2008 Stack et al. 7,445,010 B2 11/2008 Kugler et al.

11/2008 Stafford 7,449,024 B2 7,682,330 B2 3/2010 Meade et al. 7,704,264 B2 4/2010 Ewers et al. 7,708,752 B2 5/2010 Durgin 7,753,870 B2 7/2010 Demarais et al. 7,771,382 B2 8/2010 Levine et al. 9/2010 Dann et al. 7,794,447 B2 10/2010 Meade et al. 7,815,589 B2 7,815,591 B2 10/2010 Levine et al. 7,846,174 B2 12/2010 Baker et al. 7,922,650 B2 4/2011 McWeeney et al. 7,976,488 B2 7/2011 Levine et al. 7,981,163 B2 7/2011 Meade et al. 10/2011 Stack et al. 8,029,455 B2 8,043,355 B2 10/2011 Shin et al. 1/2012 Baker et al. 8,100,931 B2 8,137,301 B2 3/2012 Levine et al. 8,162,871 B2 4/2012 Levine et al. 8,282,598 B2 10/2012 Belhe et al. 8,372,087 B2 2/2013 Baker et al. 5/2013 Sharma et al. 8,447,403 B2 8,506,477 B2 8/2013 Waller et al. 8,529,431 B2 9/2013 Baker et al. 8,672,831 B2 3/2014 Baker et al. 8,721,528 B2 5/2014 Ho et al. 8,778,011 B2 7/2014 Ryan 8,784,436 B2 7/2014 Ho et al. 8,801,599 B2 8/2014 Baker et al. 8,894,670 B2 11/2014 Baker et al. 9,055,998 B2 6/2015 Baker 9,198,789 B2 12/2015 Baker et al. 9,375,338 B2 6/2016 Baker et al. 9,414,948 B2 8/2016 Baker et al. 1/2017 Baker et al. 9,545,326 B2 12/2017 Baker et al. 9,839,545 B2 9,872,787 B2 1/2018 Baker et al. 1/2019 Baker ...... A61F 5/0079 10,182,901 B2\* 2001/0020189 A1 9/2001 Taylor 3/2002 Dua et al. 2002/0032487 A1 7/2002 Gabbay 2002/0091395 A1 2/2003 Stack et al. 2003/0040804 A1 2003/0040808 A1 2/2003 Stack et al. 2003/0065359 A1 4/2003 Weller et al. 6/2003 Geitz 2003/0109935 A1 2003/0199989 A1 10/2003 Stack et al. 2003/0212450 A1 11/2003 Schlick 2004/0044357 A1 3/2004 Gannoe et al. 5/2004 DeVries et al. 2004/0087976 A1 5/2004 Kagan et al. 2004/0092892 A1 2004/0106987 A1 6/2004 Palasis et al. 6/2004 Ledergerber 2004/0116999 A1 6/2004 Stack et al. 2004/0117031 A1 2004/0138761 A1 7/2004 Stack et al. 7/2004 Stack et al. 2004/0143342 A1 7/2004 Kagan et al. 2004/0148034 A1 9/2004 Stack et al. 2004/0172141 A1 2004/0210111 A1 10/2004 Okada 2004/0220682 A1 11/2004 Levine et al. 1/2005 Edoga et al. 2005/0004582 A1 2/2005 Ravo 2005/0043683 A1 2005/0080395 A1 4/2005 Levine et al. 2005/0096728 A1 5/2005 Ramer 6/2005 Meade et al. 2005/0125020 A1 9/2005 Kugler et al. 2005/0197715 A1 2005/0228504 A1 10/2005 Demarais 2005/0245788 A1 11/2005 Gerber 11/2005 Starkebaum et al. 2005/0245957 A1 2005/0247320 A1 11/2005 Stack et al. 11/2005 Vaughan et al. 2005/0251165 A1 2005/0251176 A1 11/2005 Swanstrom et al. 2005/0283235 A1 12/2005 Kugler et al. 1/2006 Gostout et al. 2006/0020277 A1 2/2006 Whitehurst et al. 2006/0036293 A1 2006/0064120 A1 3/2006 Levine et al. 2006/0074473 A1 4/2006 Gertner 4/2006 Gertner 2006/0089571 A1 6/2006 Lowe et al. 2006/0142844 A1 7/2006 Durgin 2006/0149307 A1 7/2006 Kagan et al. 2006/0155375 A1

(56)	References Cited	FOREIGN PATENT DOCUMENTS
U.S. F	PATENT DOCUMENTS	EP 2240215 B1 1/2014 JP 2660101 6/1997
2006/0161139 A1	7/2006 Levine et al.	JP 2000101 0/1997 JP 2006-103873 A 4/2006
2006/0191139 A1	8/2006 Gannoe et al.	JP 2007508053 A 4/2007
2006/0247721 A1	11/2006 Maschino et al.	JP 2011509758 A 3/2011
2006/0253131 A1	11/2006 Wolniewicz, III	RU 2045233 C1 10/1995
2006/0253142 A1	11/2006 Bjerken	RU 94026119 A 8/1996 RU 2386455 4/2010
2006/0264699 A1	11/2006 Gertner	WO WO 93/22986 11/1993
2006/0265082 A1 2007/0005147 A1	11/2006 Meade et al. 1/2007 Levine et al.	WO WO 94/12136 6/1994
2007/0003147 A1 2007/0010866 A1	1/2007 Dann et al.	WO WO 01/35834 A1 5/2001
2007/0088428 A1	4/2007 Teichman	WO WO 01/85034 A1 11/2001 WO WO 02/060328 A1 8/2002
2007/0112409 A1	5/2007 Wu et al.	WO WO 02/000326 711 0/2002 WO 02/094105 A2 11/2002
2007/0123994 A1	5/2007 Ortiz et al.	WO WO 2004/019826 A1 3/2004
2007/0166396 A1 2007/0179590 A1*	7/2007 Badylak et al. 8/2007 Lu A61F 2/91	WO WO 2004/064680 A1 8/2004
2007/01/9390 A1	623/1.16	WO WO 2004/064685 8/2004 WO WO 2005/037152 A1 4/2005
2007/0198035 A1	8/2007 Threlkeld	WO WO 2006/044640 A1 4/2006
2007/0208429 A1	9/2007 Leahy	WO WO 2006/078672 A1 7/2006
	10/2007 Raju	WO WO 2007/092390 A2 8/2007
	11/2007 Rahmani	WO WO 2008/100984 A2 8/2008 WO WO 2008/101048 A2 8/2008
	11/2007 Stack et al. 12/2007 Baker A61F 2/04	WO = WO 2009/101079 A2 = 9/2009
2007/02/3710 711	600/37	WO WO 2009/048398 A1 4/2009
2008/0015523 A1	1/2008 Baker	WO WO 2009/091899 A2 7/2009 WO WO 2010/117641 A2 10/2010
2008/0015618 A1	1/2008 Sonnenschein et al.	WO WO 2010/11/041 A2 10/2010 WO WO 2011/056608 A1 5/2011
2008/0015633 A1	1/2008 Abbott et al.	WO WO 2011/063307 A1 5/2011
2008/0065122 A1 2008/0065136 A1	3/2008 Stack et al. 3/2008 Young	WO WO 2011/097209 A1 8/2011
2008/0005150 A1	9/2008 Houng 9/2008 Baker	WO WO 2011/116025 A1 9/2011 WO WO 2012/044917 A1 4/2012
2008/0312678 A1	12/2008 Pasricha	WO WO 2012/044317 A1 4/2012 WO WO 2012/136249 A1 10/2012
2009/0138071 A1	5/2009 Cheng et al.	WO WO 2012/162114 A1 11/2012
2009/0177215 A1	7/2009 Stack et al.	WO WO 2013/090190 A1 6/2013 WO WO 2013/134227 A1 9/2013
2009/0187230 A1 2009/0240340 A1	7/2009 Dilorenzo 9/2009 Levine et al.	WO WO 2013/134227 A1 9/2013 WO WO 2015/031077 A1 3/2015
	10/2009 Levine et al.	WO WO 2016/109346 A1 7/2016
2009/0270818 A1	10/2009 Duke	
2010/0010298 A1	1/2010 Bakos et al.	OTHER PUBLICATIONS
2010/0030017 A1 2010/0063518 A1	2/2010 Baker et al. 3/2010 Baker et al.	
2010/0003318 A1 2010/0114124 A1	5/2010 Baker et al.	International Preliminary Report on Patentability and Written Opin-
2010/0114130 A1	5/2010 Meade et al.	ion of the International Searching Authority from corresponding
2010/0198237 A1	8/2010 Baker et al.	Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/
2010/0256775 A1	10/2010 Belhe et al.	38480, dated Nov. 29, 2013.
2010/0280313 A1 2011/0004146 A1	11/2010 Gasche et al. 1/2011 Priplata et al.	"Obesity: Super-Sized Medical Device Market", Start-Up, Mar.
2011/0009690 A1	1/2011 Belhe et al.	2003, Technology Strategies (Long Article), pp. 1-10 and a cover
2011/0092879 A1	4/2011 Baker et al.	page. Andrew S. Lowe, M.D. and Maria B. Sheridan, M.D., "Esphogeal
2011/0264234 A1	10/2011 Baker et al.	Stenting", Seminars in Interventional Radiology, vol. 21, No. 3,
2012/0083871 A1 2012/0089168 A1	4/2012 Ryan 4/2012 Baker et al.	2004, pp. 157-166.
2012/0089108 A1 2012/0095497 A1	4/2012 Baker et al. 4/2012 Babkes et al.	"Polyflex® Espohageal Stent", Silicone Covered Stent, Boston
2012/0093197 711 2012/0191213 A1	7/2012 Baker et al.	Scientific, three pages (2003).
2012/0191215 A1	7/2012 Baker et al.	Andrew F.R. Dixon, Johgn B. Dixon, and Paul E. O'Brien, "Lapa-
2012/0203061 A1	8/2012 Birk	roscopic Adjustable Gastric Banding Induces Prolonged Satiety: A
2012/0289991 A1	11/2012 Baker	Randomized Blind Crossover Study", The Journal of Clinical
2013/0123811 A1	5/2013 Baker et al.	Endocrinology & Metabolism, pp. 813-819, 2005. Roman, S. et al., "Intragastric balloon for 'non-morbid' obesity: a
2013/0296913 A1 2013/0324902 A1	11/2013 Foote et al. 12/2013 Miller et al.	retrospective evaluation of tolerance and efficacy," Obes. Surg.,
2013/0324302 A1 2014/0018611 A1	1/2014 Baker et al.	2004, 14(4), 539-44, abstract, [on-line], [found Apr. 17, 2009, from
2014/0114230 A1	4/2014 Baker et al.	Pubmed database].
2014/0121585 A1	5/2014 Baker et al.	Busetto, L. et al., "Preoperative weight loss by intragastric balloon
2014/0309681 A1	10/2014 Baker et al.	in super-obese patients treated with laparoscopic gastric banding: a
2015/0025313 A1	1/2015 Baker et al.	case-control study," Obes Surg., 2004, 14(5), 671-6, abstract, [on-
2015/0039092 A1 2015/0182239 A1	2/2015 Baker et al.	line], [found Apr. 17, 2009, from Pubmed database].
2015/0182239 A1 2016/0038325 A1	7/2015 Baker et al. 2/2016 Baker et al.	Summary of Official Action dated Oct. 29, 2009, from the Israel Patent Office in a patent application corresponding to the present
2016/0036323 A1*	6/2016 Baker A61F 5/0079	
	601/148	
2016/0262867 A1	9/2016 Baker et al.	Stenting," annotated by Israel Patent Office (2004).
	11/2016 Baker et al.	Abstract and claims of U.S. Pat. No. 6,960,233 annotated by the
ZU17/U172723 Al	6/2017 Foote et al.	Israel Patent Office (Nov. 1, 2005).

### (56) References Cited

#### OTHER PUBLICATIONS


Schembre, Drew, "Advances in Esophageal Stenting: the Evolution of Fully Covered Stents for Malignant and Benign Disease," Adv. Ther., Springer Healthcare, Apr. 1, 2010, pp. 1-13.


International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US08/53912, completed Aug. 19, 2009.


International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US05/36991, completed Mar. 6, 2006.


- S. Fukudo, T. Nomura, M. Hongo, "Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowl syndrome", Jan. 19, 1998.
- D.G. Maxton, D.F. Martin, P.J. Whorwell, M. Godfrey. "Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms", Aug. 3, 1990.


<sup>\*</sup> cited by examiner















































US 11,129,703 B2









Fig. 20














## INTRALUMINAL DEVICE AND METHOD OF **FIXATION**

#### CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/163,030, filed on May 24, 2016, which is a continuation of U.S. patent application Ser. No. 14/118,731, filed on Nov. 19, 2013, now U.S. Pat. No. 9,375,338, issued 10 on Jun. 28, 2016, which claims the priority benefits of International Patent Application No. PCT/US2012/038480, filed on May 18, 2012, which claims priority from U.S. patent application Ser. No. 61/488,194, filed on May 20, 2011, and U.S. patent application Ser. No. 61/607,338, filed 15 on Mar. 6, 2012, the disclosures of which are hereby incorporated herein by reference in their entirety.

#### BACKGROUND OF THE INVENTION

The present invention is directed to an intraluminal device and method and, in particular, to such a device and method that are useful in a lumen that is subject to peristaltic waves to resist distal migration of the device from the action of the peristaltic waves. While the invention is illustrated as a 25 bariatric device and method having an esophageal member that is adapted to be positioned in the esophagus, it may be useful with other devices and methods in the esophagus as well as devices and methods useful in other lumens that are subject to peristaltic waves.

### SUMMARY OF THE INVENTION

An intraluminal device adapted to be deployed at a portion and a GE junction between the esophagus and the cardiac portion of the stomach, according to an aspect of the invention, includes a wall. The wall defines a cardiac member that is configured to the size and shape of the cardiac portion of the stomach and an esophageal member that is 40 configured to the size and shape of a portion of the esophagus. A connector is connected with the esophageal portion and the cardiac portion. A fixation system is configured to resist distal migration of the wall. The fixation system includes a wall characteristic of the wall that is configured 45 to facilitate tissue ingrowth. The fixation system further includes temporary fixation configured to at least temporarily resist distal migration of the wall while tissue ingrowth occurs at the wall characteristic.

The temporary fixation may include at least one mucosal 50 capture opening in the wall at the esophageal member that is configured to capture mucosa to at least temporarily resist distal migration of the wall. The temporary fixation may include a suture looped around the esophageal member and adapted to be attached to the recipient to at least temporarily 55 resist distal migration of the wall. The suture may be adapted to be attached to a molar or orthodontic bracket of the recipient.

The connector may include at least two elongated members that pass through the GE junction and are configured to 60 not inhibit operation of the GE Junction. The wall may be impregnated with an anti-spasm medication or coated with an anti-spasm medication.

The wall at the esophageal member may be defined by an outwardly expanding mesh that is covered by a cover that 65 defines a proximal end portion and a distal end portion of the esophageal member. The wall at the esophageal member

may have a transition zone at at least one of the end portions of said esophageal member. The wall applies different stress on the esophagus at the transition zone than inward of the transition zone. The wall may apply a lower stress at the transition zone than inward of the transition zone. The mesh may have a non-uniform cell structure with the cell structure being less dense at the transition zone than inward of the transition zone thereby defining the transition zone at least in part.

The wall at the esophageal member may be adapted to reduce esophageal spasm resulting from peristalsis including minimizing progression of the peristalsis at the esophageal member. The wall at the esophageal member may define an edge portion defining angulations therein. The angulations are adapted to reduce the spasm of the esophagus. The angulations may be a bevel or a scalloped shape. The edge portion may be at a proximal end portion of the wall with respect to the peristalsis.

An intraluminal device adapted to be deployed at a 20 recipient having an esophagus, a stomach with a cardiac portion and a GE junction between the esophagus and the cardiac portion of the stomach, according to an aspect of the invention, includes an esophageal member with an esophageal surface defined by an esophageal wall. The esophageal surface is configured to generally conform to the shape and size of a portion of the esophagus. A cardiac member has a cardiac wall defining a cardiac surface that is configured to generally conform to the shape and size of a portion of the cardiac region of the stomach. A connector is connected with 30 the esophageal member and the cardiac member. The esophageal wall is defined by a support structure and a cover over the support structure. The at least one opening is defined in a cover. The support structure is defined by a plurality of intersecting mesh portions thereby defining a recipient having an esophagus, a stomach with a cardiac 35 plurality of rectilinear polygons. The esophageal wall has at least one opening therein between end portions thereof. The at least one opening is the size of a plurality of adjacent ones of the polygons. Tissue ingrowth will occur around the intersecting mesh portions in the at least one opening. Temporary fixation fixes the intraluminal device in the recipient until tissue ingrowth occurs around the intersecting mesh portions.

> The temporary fixation may be one or more mucosal capture openings in the esophageal wall that do not have intersection mesh portions. The mucosal capture opening captures mucosa. The temporary fixation may be a suture looped around the esophageal member and attached to the recipient. The suture may be attached to a molar or orthodontic bracket of the recipient.

> The at least one opening may be the size of at least three of adjacent ones of the polygons arranged in shapes of a diamond, a cross, a line and/or an "H" shape. The at least three of the adjacent ones of the polygons may be at least five adjacent ones of the polygons. The at least one opening may be at least three openings distributed radially around the esophageal member. The at least one opening may be configured to regulate mucosal ingrowth on the support structure. The at least one opening may be configured to regulate mucosal ingrowth by having a dimension that is less than an amount that would promote uncontrolled mucosal ingrowth.

> The esophageal wall may have a transition zone at one or both end portions of the esophageal wall. The esophageal wall applies different stress on the esophagus at the transition zone than inward of the transition zone. The esophageal wall may apply a lower stress at said transition zone than inward of said transition zone. The mesh may have a

non-uniform cell structure wherein the cell structure is less dense at the transition zone than inward of the transition zone thereby defining said transition zone at least in part.

The esophageal wall may reduce esophageal spasm resulting from peristalsis including minimizing progression of the 5 peristalsis at the esophageal wall. The esophageal wall may define an edge portion with angulations therein. The angulations reduce the spasm of the esophagus. The angulations may be a bevel or a scalloped shape. The edge portion may be at a proximal end portion of the wall with respect to the 10 peristalsis.

At least one of said walls may be impregnated with an anti-spasm medication or coated with an anti-spasm medication.

A method of fixation of an intraluminal device at a 15 the side thereof; recipient having an esophagus, a stomach with a cardiac portion and a GE junction between the esophagus and the cardiac portion of the stomach, according to an aspect of the invention, includes deploying the intraluminal device to the recipient. The intraluminal device has a wall defining a 20 cardiac member that is configured to the size and shape of the cardiac portion of the stomach and deployed to the cardiac portion of the stomach. The intraluminal device has an esophageal member that is configured to the size and shape of a portion of the esophagus and deployed to the 25 esophagus. The intraluminal device includes a connector connected with the esophageal portion and cardiac portion and deployed to the GE junction. The wall is fixed to the recipient to resist distal migration of the intraluminal device. The fixing includes the wall having a wall characteristic that 30 is configured to facilitate tissue ingrowth to fix the wall to the recipient. The wall is temporarily fixed to the recipient to resist distal migration of said wall while tissue ingrowth occurs at the wall characteristic.

A method of fixation of an intraluminal device at a 35 embodiment thereof; recipient having an esophagus, a stomach with a cardiac portion and a GE junction between the esophagus and the cardiac portion of the stomach, according to an aspect of the invention, includes deploying the intraluminal device to the recipient. The intraluminal device has an esophageal mem- 40 ber with an esophageal surface defined by an esophageal wall. The esophageal surface is configured to generally conform to the shape and size of a portion of the esophagus and deployed to the esophagus. The intraluminal device includes a cardiac member has a cardiac wall defining a 45 cardiac surface that is configured to generally conform to the shape and size of the cardiac portion of the stomach and deployed to the cardiac portion of the stomach. The intraluminal device includes a connector that is connected with the esophageal member and the cardiac member and deployed 50 to the GE junction. The esophageal wall is fixed to the recipient to resist distal migration of the esophageal wall. The esophageal wall is defined by a support structure and a cover over the support structure. The support structure is defined by a plurality of intersecting mesh portions thereby 55 defining a plurality of rectilinear polygons. The esophageal wall has at least one opening therein between end portions thereof. The at least one opening is defined in the cover. The at least one opening is the size of a plurality of adjacent ones of the polygons. Tissue ingrowth will occur around the 60 intersecting mesh portions in the at least one opening. The wall is temporarily fixed to the recipient to resist distal migration of the wall while tissue ingrowth occurs around the intersecting mesh portions.

These and other objects, advantages and features of this 65 invention will become apparent upon review of the following specification in conjunction with the drawings.

4

#### BRIEF DESCRIPTION OF THE DRAWINGS

- FIG. 1 is a side elevation of an intraluminal device according to an aspect of the invention;
- FIG. 2 is an enlarged perspective view of the area designated II in FIG. 1;
- FIG. 3 is the same view as FIG. 1 of an alternative embodiment thereof;
- FIG. 4 is a side elevation of a bariatric device according to an aspect of the invention;
- FIG. 5 is a perspective view of the bariatric device in FIG. 4;
- FIG. 6 is a perspective view of an esophageal member of an alternative embodiment of a bariatric device taken from the side thereof:
- FIG. 7 is an end view of the esophageal member in FIG. 6.
- FIG. 8 is a side elevation of a bariatric device incorporating the esophageal member of FIG. 6;
- FIG. 9 is a view of the bariatric device of FIG. 8 deployed in a recipient;
- FIG. 10 is a side elevation of a flattened esophageal member showing a pattern of openings in a wall thereof;
- FIG. 11 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 12 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 13 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 14 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 15 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 16 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 17 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 18 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 19 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 20 is the same view as FIG. 1 of an alternative embodiment thereof;
- FIG. 21 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 22 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 23 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 24 is the same view as FIG. 10 of an alternative embodiment thereof;
- FIG. 25 is the same view as FIG. 10 of an alternative embodiment thereof; and
- FIG. **26** is the same view as FIG. **10** of an alternative embodiment thereof.

# DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring now to the drawings and the illustrative embodiments depicted therein, an intraluminal device 20 includes a member, such as an esophageal member 22, having a surface 24 defined by a wall 26 having opposite end portions made up of a proximal end portion 30 and a distal end portion 32 (FIGS. 1 and 2). Surface 24 is configured to generally conform to the shape and size of a portion of the lumen in which it is to be deployed. In particular, surface 24

is configured to generally conform to the shape and size of a portion of a lumen that experiences peristalsis. Examples of such lumen include the esophagus, the colon, other portions of the intestines, ureter, urethra, biliary duct, fallopian tube, vas deferens, and the like.

End portions 30, 32 are spaced apart along an axis A in the direction of peristaltic movement along the lumen in which device 20 is deployed. Wall 26 is defined by a support structure, such as a wire mesh 34, made from Nitinol wire, or the like, and a cover 35 over support structure 34. In the 10 illustrated embodiment, cover 35 is a form of silicone or other flexible biologically inert substance that is applied, for example, to about 0.4 millimeter thickness. Cover 34 may have one or more overlapped portions at proximal end are generally not adhered to each other where overlapped except at adhesive areas 37. This allows proximal end portion 30 and/or distal end portion 32 to be more pliant which produces transition zones 28 between device 20 and the lumen in which the device is deployed. Such transition 20 zones are believed to minimize spasm as disclosed in commonly assigned U.S. patent application Ser. No. 61/388, 857, filed Oct. 1, 2010, the disclosure of which is hereby incorporated herein by reference in its entirety. Transition zone 28 at proximal end portion 30 may additionally include 25 a pattern 68 to mesh 34 that is less dense, or more open, than the pattern of the rest of mesh 34.

Intraluminal device 20 includes at least one opening 75 in cover 35. Opening 75 is between end portions 30, 32 and is provided in order to resist peristaltic waves causing distal migration of the device 20. Opening 75 provides an area where the mucosa of the lumen can grip device 20 between end portions 30, 32 by pooching into opening 75. This provides for capture of the mucosa of the lumen in which device 20 is positioned using the principles set forth in U.S. 35 Patent Application Publication No. 2010/0198237 A1 entitled MUCOSAL CAPTURE FIXATION OF MEDICAL DEVICE, the disclosure of which is hereby incorporated herein by reference. The placement of opening 75 between end portions 30, 32 further assists in anchoring of the 40 intraluminal device 20 within the lumen. While the principle of operation is not entirely known, it is believed that as the peristaltic wave passes down the lumen, it creates passing areas of increased inward pressure alternating with areas of decreasing pressure. Without opening 75, it may be possible 45 to have an area of increasing pressure between end portions 30, 32 with areas of decreasing pressure nearby end portions 30, 32 thereby not having any portion of device 20 to resist distal migration, even were end portions 30, 32 to be left uncovered.

In the illustrated embodiment, opening 75 has a width W parallel to the axis A of device 20 that aligns with the direction of movement of the peristaltic wave. Opening 75 forms a pattern that is distributed radially around wall 26. This is accomplished in the illustrated embodiment by 55 opening 75 being in the form of a band that extends around the wall. However, other shapes are possible as will be described in detail below.

Opening 75 is illustrated as a through-opening that promotes tissue ingrowth around the wires defining structure 60 34. Opening 75 may alternatively be configured to regulate the amount of mucosa ingrowth attachment to mesh 34, such as for ease of removal. This reduces the amount of effort required to remove device 20 from the lumen. One way to regulate mucosa ingrowth is to select width W of opening 75 65 to be less than a particular width. In the illustrated embodiment, width W is approximately 7.5 millimeters, but other

dimensions are possible. Alternatively, or additionally, cover 35 may be essentially removed outwardly of mesh 34 at opening 75, but be present inwardly of mesh 75. This would allow the mucosa to pooch into opening 75, but be generally inhibited from growing around the strands of the mesh. However, even if mucosal ingrowth around the strands of the mesh were to occur which occurs when portions of the mucosa grow into each other in a manner that encompasses strands of mesh 34, which would aid in long term placement of device 20, techniques are known to remove the ingrowth, such as cautery. Also, a tool such as an endoscope, or the like, can be inserted between wall 26 and the esophagus in order to gently pry the mucosa away from opening 75.

In the illustrated embodiment, wall 26 is generally cylinportion and/or distal end portion 32. The layers of cover 35 15 drical with respect to axis A and opening 75 is in the shape of an open band that extends substantially entirely around wall 26 generally perpendicular to axis A. However, other shapes will be apparent to the skilled artisan. For example, discrete openings can be arranged in a pattern that extends substantially entirely around wall 26 generally perpendicular to axis A, as will be described in detail below.

In an alternative embodiment, an intraluminal device 120 includes a surface 124 defined by a wall 126 made up of a support structure, such as mesh 134 covered by a cover 135 (FIG. 3). Device 120 includes a plurality of openings that form patterns that extend around the circumference of wall **126** perpendicular to axis A that extends in the direction of movement of the peristaltic wave. These patterns are in the form of open bands 175 between a proximal end portion 130 and distal end portion 132. Bands 175 extend substantially around wall 126 generally perpendicular to axis A. Each opening 175 has a dimension W perpendicular to axis A that tends to regulate mucosa ingrowth, although other dimensions may be selected. Bands 175 are spaced apart a distance S that are on the order of magnitude of the wavelength of a peristaltic wave. In the illustrated embodiment, distance S is greater than or equal to the wavelength of a peristaltic wave. This ensures that, when an area of decreasing pressure of the lumen wall caused by the peristaltic wave passes over one band 175, an area of increasing pressure of the lumen wall will concurrently be passing over the other band 175 and vice versa. This ensures that there will typically be an area of increasing pressure acting on a band 175 to anchor the wall even with an area of decreasing pressure acting on the other band as the peristaltic wave passes in order to resist distal migration. In the illustrative embodiment, bands 175 are spaced apart a distance S that is greater than the wavelength of a peristaltic wave. By way of example, if the wavelength of the peristaltic wave is on the order of 1 to 2 50 centimeters, then distance S is approximately 2 to 3 centimeters or more. Although device 120 is illustrated with two bands 175, it should be understood that 3 or more bands may be used. Also, other patterns, such as discrete openings may be used.

In one application, intraluminal device 20 is a bariatric device and member 22 is an esophageal member that is configured to generally conform to the shape and size of the distal portion of the esophagus. As disclosed in commonly assigned U.S. Patent Application Publication No. 2007/ 0293716 A1, the disclosure of which is hereby incorporated herein by reference, such bariatric device stimulates receptors with surface 24 in order to influence a neurohormonal mechanism in the recipient sufficient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food. However, intraluminal device 20 may, alternatively, be an esophageal stent configured to treat strictures, fistulas, and the like, in the esopha-

gus. Intraluminal device 20 may, alternatively, be a colonic stent configured to treat stricture, fistulas, and the like, in the colon. Other applications will be apparent to the skilled artisan including stents configured to ureter, urethra, biliary duct, fallopian tube, vas deferens, and the like.

In another alternative embodiment, an intraluminal device 220 is in the form of a bariatric device having an esophageal member 322 having an esophageal surface 324 defined by an esophageal wall 336 (FIGS. 4 and 5). Esophageal surface 324 is configured to generally conform to the shape and size of a portion of the esophagus. Esophageal wall 336 has end portions 330, 332 that are spaced apart along an axis A in the direction of elongation of the esophagus, which is the direction of movement of the peristaltic waves. Wall 336 is defined by a support structure in the form of a mesh 334 and a cover 335 over mesh 334. Cover 335 has at least one 375 opening therein between end portions 330, 332 in order to resist peristaltic waves causing distal migration of esophageal member 322 in a similar fashion to bands 75 and 175 previously described.

Bariatric device 220 further includes a cardiac member 350 having a cardiac wall 354 defining a cardiac surface 352 that is configured to generally conform to the shape and size of a portion of the cardiac region of the stomach. Cardiac 25 surface 352 and/or esophageal surface 324 are for the purpose of influencing a neurohormonal mechanism in the recipient sufficient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food. Bariatric device **220** further includes a 30 connector 356 connected with esophageal member 322 and cardiac member 350. Connector 356 passes through the pseudo-sphincter of the gastroesophageal junction in a manner that minimizes interference therewith. Tether devices and cardiac member 350 opposite connector 356 as disclosed in U.S. Patent Application Publication No. 2010/ 0030017 A1, the disclosure of which is hereby incorporated herein by reference. Connector **356** may have a radiopaque marker, such as gold thread extending along connector 356 40 in order to allow connector 356 to be properly positioned during deployment of bariatric device 220.

In yet a further embodiment, a bariatric device 420 includes an esophageal member 422 having a cylindrically shaped wall 426 that expands to the general size and shape 45 of the esophagus and a cardiac member 450 that expands to the general size and shape of the cardiac region of the stomach (FIGS. 6-9). Members 422 and 450 are connected with a connector **456** that passes through the GE junction in a manner that does not inhibit operation of the GE junction. 50 Esophageal wall **426** is defined by a support, such as a mesh 434 that is covered by a cover such as a silicone cover 435 that defines a proximal end portion 430 and a distal end portion 432 with respect to propagation of the peristaltic waves. Esophageal wall **426** includes anchoring openings 5. 475 between end portions 430, 432. Openings 475 are discrete openings that are arranged around the circumference of wall 426 in two patterns that are separated by distance S. As previously described, distance S is on the same magnitude as the peristaltic wavelength and is greater 60 than or equal to the wavelength, yet openings 475 are inboard of end portions 430, 432. One pattern of openings 475 is illustrated in FIG. 7 in which three (3) openings 475 are spaced generally equidistant radially around the circumference of wall **426**. While three (3) openings are illustrated 65 in each pattern, a greater or lesser number could be used. Also, although openings 475 of each of the two patterns are

8

generally aligned with each other in the direction of axis A, they could also be offset from each other.

In the illustrated embodiment, each opening 475 is made up of four (4) adjacent cells of mesh 434 in the form of a rectilinear polygon, such as a diamond shape. This allows pooching of the mucosa in openings 475 for immediate anchoring of esophageal member 422 and allows tissue ingrowth to occur around the wires interior to each opening 475 for longer term anchoring. In order to expedite tissue ingrowth, techniques may be used to irritate the mucosa to promote the growing together of the bulges pooching around the strands of the mesh. For example, a brush may be inserted endoscopically to the interior of esophageal member 422 to roughen the bulging mucosa. Also, various agents, such as sclerosants, may be applied to the bulging mucosa as described in U.S. Patent Application Publication 2010/0198237 A1. Also, each section of bulging mucosa may be suctioned individually, such as with an endoscope, to create a varix either by applying suction to each opening 475 or by applying suction to the entire esophageal member. A band, such as a rubber band, may be applied around the mucosa, such as from an end of an endoscope, to hold the bariatric device until tissue grows into each opening 475. At such time, the varix may fall off along with the rubber band and pass through the GI tract. Alternatively, each section of mucosa bulging into an opening 475 may be treated with injection of a bulking agent, such as various forms of injectable collagen, or the like. While the bulking agent will eventually be absorbed in the body, it will enlarge the bulging mucosa sufficiently to allow tissue in growth to occur. Other techniques will be apparent to the skilled artisan.

Connector 456 connects esophageal member 420 and cardiac member 450 in a manner that does not interfere with may be installed in situ between esophageal member 322 35 the operation of the GE junction. In the illustrated embodiment, connector 456 is made up of two or more tension members or struts 456a and 456b that are spaced apart roughly equal radial distances between the distal opening of esophageal member 422 and cardiac member 450. Struts **456***a*, **456***b* are shown oriented side-to-side in a frontal plane. If oriented in a frontal plane, one strut oriented at the greater curve will be longer in order to allow for the angled orientation of the cardiac member with respect to the esophageal member. Also, the strut 456a, 456b that is at the greater curve may be of a more flexible material than the other strut in order to conform to the curvature of the greater curve. Alternatively, the struts may be oriented anteriorposterior in a sagittal plane. If the struts are oriented on a sagittal plane, they may both be of generally the same length. The cardiac member will pivot into proper orientation against the cardiac portion of the stomach because it is free to pivot about the sagittal plane of struts 456a, 456b.

In the illustrated embodiment, tension member 456a is approximately twice the length as tension member 456b, although dimensions may vary. This produces a tilt between cardiac member 450 and the axis A passing through esophageal member 422, as best seen in FIG. 9. This allows esophageal member 422 to pull cardiac member 450 via tension members 456a, 456b in a manner that applies a pressure against all portions of the cardia surrounding the GE junction notwithstanding the natural tilt of the greater and lesser curves of the stomach. In this manner, cardiac member 450 can apply pressure on the cardiac portion of the stomach solely by the anchoring of esophageal member 422 in the esophagus by openings 475. This eliminates the need for the use of additional anchoring mechanisms, such as the tethers disclosed in U.S. Patent Application Publication No.

2010/0030017 A1. However, other anchoring mechanisms can be used such as tissue ingrowth characteristics formed in cardiac surface **452** of cardiac member **450**, or the like. In the illustrated embodiment, tension member **456***a* is 14 millimeters and tension member **456***b* is 7 millimeters. 5 Tension members **456***a*, **456***b* may be made adjustable in length using the principles disclosed in U.S. Patent Application Publication No. 2010/0030017 A1 in order to titrate the amount of satiety achieved by the recipient as set forth in U.S. Pat. No. 8,100,931, the disclosure of which is hereby 10 incorporated herein by reference.

The recipient may be instructed to avoid solid foods for one or two weeks in order to allow tissue to grow around the mesh wires in openings 75, 175, and 475. If the device does migrate prior to the formation of tissue ingrowth, the recipient is not harmed because the device will reside in the stomach. The doctor can pull the device back into position. Alternatively, the device may be removed and redeployed with a suture looped around the esophageal portion. The suture may be attached such as to a molar of the recipient or 20 a bracket of the type used by orthodontists temporarily fixed to a tooth. Such suture will be well tolerated by the recipient and can be clipped when no longer needed after tissue ingrowth has occurred.

FIG. 10 shows a bariatric device having an esophageal 25 member 422 that has been flattened for better illustration and having no mucosal capture openings.

FIG. 11 shows a bariatric device having an esophageal member 422a that has been flattened for better illustration and having mucosal capture openings 475a which are 30 defined by a "Z" pattern defined by adjacent opened cells in the esophageal wall.

FIG. 12 shows a bariatric device having a flattened esophageal member 422b having mucosal capture openings 475b that are arranged in a pattern of adjacent diamond shapes, each made up of four (4) open cells in the esophageal wall.

like.

While the foregoing description describes several embodiments of the present invention, it will be understood by those skilled in the art that variations and modifications to these embodiments may be made without departing from

FIG. 13 shows a bariatric device having a flattened esophageal member 422c having mucosal capture openings 475c that are diamond shapes, each made up of four (4) 40 adjacent open cells of the mesh, with openings 475c being arranged in patterns that are spaced apart a distance "S" that is at least on the order of magnitude of the wavelength of the peristaltic wave in the esophagus.

FIG. 14 shows a bariatric device having a flattened 45 esophageal member 422e having openings 475e, each in the shape of an "H" made up of three intersecting lines each encompassing three adjacent open cells of the mesh.

FIG. 15 shows a bariatric device having a flattened esophageal member 422f, having a plurality of openings 50 475f each in a shape of an "H" similar to openings 475e, but arranged in patterns that are spaced apart a distance "S" that is at least on the order of magnitude of the wavelength of the peristaltic wave in the esophagus.

FIG. 16 shows a bariatric device having a flattened 55 esophageal member 422g having a plurality of openings 475g each in a shape of an "H" similar to openings 475e and 475f, but with the shapes having different orientations with each other.

FIGS. 17, 18 and 19 show bariatric devices having 60 respective flattened esophageal members 422h, 422i and 422j, each having respective openings 475h, 475i, and 475j in the shape of a cross defined by intersecting lines of three (3) open cells each. However, the openings are arranged differently in each esophageal member. Other opening 65 shapes and arrangements will be apparent to the skilled arisen.

10

The esophageal member **520**, shown in FIG. **20**, is made up of sections 520a, 520b, 520c that are joined together with flexible struts 456. Each section 520a, 520b, 520c has an opening 175 so that openings 175 are spaced apart a distance S that is at least an order of magnitude of an esophageal peristaltic wavelength. In this manner, at least one opening 175 will be firmly engaged by the esophagus as the peristaltic wave passes. While illustrated as connected by separated struts 556, the sections could be joined by a common cover, but just be made up of separate mesh sections, which could themselves be made up of Nitinol wire mesh, stainless steel or polymers. Also, esophageal member **520** is shown with two struts 556a, 556b that connect member 520 with a cardiac member (not shown in FIG. 20). However, it should be understood that each section 520a, 520b and 520c may individually be connected by struts to the cardiac member so that there is always tension applied to the cardiac member as the esophageal peristaltic wave passes.

FIGS. 21-26 show a variety of flattened esophageal members 422K, 422M, 4220, 422Q, 422S and 422T, each with some form of opening 475L, 476N, 475P, 475R, and 475T that provide openings which expose at least a portion of the mesh on one cover surface for mucosal capture and ingrowth about the wires of the mesh. At least some of the flattened esophageal members have openings 475K, 475M, 4750, 475Q and 475S, which do not get traversed by a mesh section and are intended primarily for mucosa capture. The openings 475K, 475M, 4750, 475Q and 475S are large enough that a larger portion of the mucosa may be captured therein for temporary fixation until tissue ingrowth occurs in all of the openings and may be aided by suction, injection by a collagen filler to make the mucosa larger in diameter, or the like.

While the foregoing description describes several embodiments of the present invention, it will be understood by those skilled in the art that variations and modifications to these embodiments may be made without departing from the spirit and scope of the invention, as defined in the claims below. The present invention encompasses all combinations of various embodiments or aspects of the invention described herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment may be combined with any and all other elements of any of the embodiments to describe additional embodiments.

The invention claimed is:

1. An intraluminal device adapted to be deployed in a lumen that is subject to peristaltic waves, the intraluminal device comprising:

an esophageal member with an esophageal surface defined by an esophageal wall, said esophageal surface being configured to generally conform to the shape and size of a portion of the esophagus;

a cardiac member having a cardiac wall defining a cardiac surface that is configured to generally conform to the shape and size of a portion of the cardiac region of the stomach;

a connector connected with said esophageal member and said cardiac member;

wherein said esophageal wall is defined by a mesh and a cover over said mesh, wherein said esophageal wall having at least one opening therein between end portions thereof, said at least one opening defined in said cover exposing said mesh in said at least one opening; and

- temporary fixation that is adapted to fixing said intraluminal device in the lumen until tissue ingrowth occurs to said mesh in said at least one opening.
- 2. The intraluminal device as claimed in claim 1, wherein said temporary fixation comprises a suture attached to the 5 recipient to at least temporarily resist distal migration of said wall.
- 3. The intraluminal device as claimed in claim 1, wherein said connector comprises at least two spaced apart elongated members that are configured to pass through the GE junction 10 and not inhibit operation of the GE junction.
- 4. The intraluminal device as claimed in claim 1, wherein said at least one opening comprises at least two openings that are on opposite sides of said esophageal wall from each other.
- 5. The intraluminal device as claimed in claim 4, wherein said at least one opening comprises at least four openings that are offset from each other both axially around said esophageal wall and two of said openings offset along an axis of elongation of the esophageal wall from the other two 20 of said openings.
- 6. The intraluminal device as claimed in claim 5, wherein said mesh is comprises a wire mesh having a plurality of intersecting mesh portions thereby defining a plurality of rectilinear polygons, a plurality of adjacent ones of said 25 polygons exposed in said at least one opening.
- 7. The intraluminal device as claimed in claim 6, wherein said plurality of adjacent ones of said polygons comprising at least seven of said polygons.
- 8. The intraluminal device as claimed in claim 6, wherein 30 said plurality of adjacent ones of said polygons comprises more than seven of said polygons.
- 9. The intraluminal device as claimed in claim 1, wherein said mesh comprises a wire mesh having a plurality of intersecting mesh portions thereby defining a plurality of 35 rectilinear polygons, a plurality of adjacent ones of said polygons exposed in said at least one opening.
- 10. The intraluminal device as claimed in claim 9, wherein said plurality of adjacent ones of said polygons comprising at least seven of said polygons.
- 11. The intraluminal device as claimed in claim 9, wherein said plurality of adjacent ones of said polygons comprises more than seven of said polygons.
- 12. A method of fixation of an intraluminal device deployed in a lumen that is subject to peristaltic waves, the 45 intraluminal device having an esophageal member with an esophageal surface defined by an esophageal wall, said esophageal surface being configured to generally conform to the shape and size of a portion of the esophagus, a cardiac member having a cardiac wall defining a cardiac surface that 50 is configured to generally conform to the shape and size of a portion of the cardiac region of the stomach and a connector connected with said esophageal member and said cardiac member, said method comprising:
  - said esophageal wall being defined by a mesh and a cover 55 over said mesh, wherein said esophageal wall having at least one opening therein between end portions thereof, said at least one opening defined in said cover exposing said mesh at said at least one opening; and

12

- temporarily fixing said esophageal wall in the lumen thereby resisting distal migration of said wall while tissue ingrowth occurs to said mesh in said at least one opening.
- 13. The method as claimed in claim 12, wherein said temporarily fixing comprises attaching the intraluminal device to the recipient with a suture to at least temporarily resist distal migration of said intraluminal device.
- 14. The method as claimed in claim 12 including irritating the lumen at said mesh at said at least one opening in order to expedited tissue ingrowth.
- 15. The method as claimed in claim 14, wherein said irritating the lumen at said mesh at said at least one opening comprises applying suction to said at least one opening.
  - 16. The method as claimed in claim 14, wherein said irritating the lumen comprises applying suction to the entire esophageal member.
  - 17. The method as claimed in claim 14, wherein said irritating the lumen comprises applying an irritating agent to the lumen at said at least one opening.
  - 18. The method as claimed in claim 17, wherein said agent comprises a sclerosant.
  - 19. The method as claimed in claim 12, wherein said connector comprises at least two spaced apart elongated members and pass in the connector through the GE junction.
  - 20. The method as claimed in claim 12, wherein said at least one opening comprises at least two openings that are on opposite sides of said esophageal wall from each other.
  - 21. The method as claimed in claim 20, wherein said at least one opening comprises at least four openings that are offset from each other both axially around said esophageal wall and two of said openings offset along an axis of elongation of the esophageal wall from the other two of said openings.
  - 22. The method as claimed in claim 20, wherein said mesh is comprises a wire mesh having a plurality of intersecting mesh portions thereby defining a plurality of rectilinear polygons, a plurality of adjacent ones of said polygons exposed in said at least one opening.
  - 23. The method as claimed in claim 22, wherein said plurality of adjacent ones of said polygons comprising at least seven of said polygons.
  - 24. The method as claimed in claim 22, wherein said plurality of adjacent ones of said polygons comprises more than seven of said polygons.
  - 25. The method as claimed in claim 12, wherein said mesh is comprises a wire mesh having a plurality of intersecting mesh portions thereby defining a plurality of rectilinear polygons, a plurality of adjacent ones of said polygons exposed in said at least one opening.
  - 26. The method as claimed in claim 25, wherein said plurality of adjacent ones of said polygons comprising at least seven of said polygons.
  - 27. The method as claimed in claim 25, wherein said plurality of adjacent ones of said polygons comprises more than seven of said polygons.

\* \* \* \* \*